Jazz Pharmaceuticals (JAZZ) Non-Current Deferred Tax Liability (2012 - 2026)

Jazz Pharmaceuticals' Non-Current Deferred Tax Liability history runs 15 years deep, the most recent figure standing at $547.7 million for Q1 2026.

• In Q1 2026, Non-Current Deferred Tax Liability fell 18.35% year-over-year to $547.7 million; the TTM figure through Mar 2026 stood at $547.7 million (down 18.35% YoY), while the FY2025 annual figure was $594.5 million, down 49.99% from the prior year.
• Non-Current Deferred Tax Liability was $547.7 million for Q1 2026 at Jazz Pharmaceuticals, down from $594.5 million in the prior quarter.
• In the past five years, Non-Current Deferred Tax Liability ranged from a high of $1.4 billion in Q4 2023 to a low of $547.7 million in Q1 2026.
• Historically, Non-Current Deferred Tax Liability has averaged $879.8 million across 5 years, with a median of $841.2 million in 2023.
• Biggest YoY gain for Non-Current Deferred Tax Liability was 1011.84% in 2022; the steepest drop was 50.37% in 2022.
• A 5-year view of Non-Current Deferred Tax Liability shows it stood at $944.3 million in 2022, then soared by 46.73% to $1.4 billion in 2023, then dropped by 14.2% to $1.2 billion in 2024, then sank by 49.99% to $594.5 million in 2025, then declined by 7.87% to $547.7 million in 2026.
• The last three Non-Current Deferred Tax Liability figures came in at $547.7 million (Q1 2026), $594.5 million (Q4 2025), and $629.0 million (Q3 2025), per Business Quant data.